Silence Therapeutics PLC Further US patents granted (8740T)
October 18 2017 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 8740T
Silence Therapeutics PLC
18 October 2017
Further US patents granted
18 October 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that the US Patent and Trade Mark Office
yesterday granted US patent application 15/589,968 as US Patent
9,790,501 and US patent application 15/594,438 as US Patent
9,790,505.
Silence previously reported issuance of a notice of allowance
for US patent application 15/589,968 on 15 August 2017 and for US
patent application 15/594,438 on 11 September 2017.
The allowed claims of US Patents 9,790,501 and 9,790,505 will
provide Silence with further protection for its innovative chemical
modification technology in the US. Silence believes that these
newly granted claims are relevant to third-party RNAi medicines,
including Alnylam Pharmaceuticals' products such as Patisiran,
Fitusiran, Inclisiran, Givosiran and Cemdisiran.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"These grants provide further protection for our US patent
estate. We now have ten granted US patents, one US patent
application, three granted European patents and four European
patent applications encompassing our chemical modification
technology. Our chemical modification patent portfolio also
encompasses patents and patent applications in the following
countries: Australia, Brazil, Canada, China, Israel, India, Japan,
Korea, Mexico and South Africa.
"We continue to believe that several third party late-stage RNAi
candidates require licences under our chemical modification patent
portfolio. This includes Alnylam Pharmaceuticals' products such as
Patisiran, Fitusiran, Inclisiran, Givosiran and Cemdisiran."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLBDGXXBBGRR
(END) Dow Jones Newswires
October 18, 2017 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024